Loading
Life sciences · Journal article
Cell Death and Disease · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Breast cancer remains a leading cause of cancer-related mortality in women, with triple-negative breast cancer (TNBC) representing the most aggressive subtype due to the absence of effective targeted therapies. Human cytomegalovirus (HCMV) has increasingly been implicated in tumor progression; however, its mechanistic contribution to breast cancer pathogenesis remains poorly understood. Here, we investigated whether HCMV promotes TNBC-associated phenotypic reprogramming through modulation of key prognostic receptors and tumor-associated cellular pathways. Using transcriptomic, proteomic, molecular, and functional analyses in luminal (MCF7) and HER2-positive (SKBR3) breast cancer models, we demonstrate that HCMV infection induces extensive host-cell reprogramming characterized by suppression of ESR1, PGR, and ERBB2 expression at both transcript and protein levels, resulting in a receptor-suppressed state with selected TNBC-associated molecular features. Mechanistically, HCMV immediate-early (IE) proteins and the viral miRNAs hcmv-miR-US25-2-3p, hcmv-miR-UL36-3p, and hcmv-miR-UL22A-3p mediated repression of ESR1 and PGR. In contrast, ERBB2 downregulation occurred indirectly through virus-mediated suppression of the EGFR/CyclinD1/CDK4/6 axis, resulting in stabilization of the RB/E2F4 repressor complex at the ERBB2 promoter. Beyond receptor suppression, HCMV infection induced extensive inflammatory, metabolic, and epithelial-mesenchymal transition (EMT)-associated remodeling consistent with a state of virus-driven phenotypic plasticity. Although infected cells displayed reduced proliferative and metabolic activity, they exhibited enhanced invasion, EMT-associated transcriptional reprogramming, and increased metastatic dissemination in zebrafish xenograft models. Elevated TGFβ signaling and partial EMT-like states likely contributed to this invasive phenotype. Collectively, our findings identify multiple viral mechanisms through which HCMV promotes TNBC-associated cellular reprogramming and metastatic behavior. These results support a previously unrecognized role for HCMV in driving aggressive breast cancer phenotypes and highlight HCMV-targeted therapeutic strategies as potential approaches for HCMV-positive TNBC.